Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial

COMMENTED

Cardiovascular Risk and Diseases

Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Lancet Diabetes Endocrinol

Hauge JW, Borgeraas H, Birkeland KI, Johnson LK, Hertel JK, Hagen M, Gulseth HL, Lindberg M, Lorentzen J, Seip B, Kolotkin RL, Svanevik M, Valderhaug TG, Sandbu R, Hjelmesæth J, Hofsø D

doi: 10.1016/S2213-8587(24)00396-6

Cardiovascular Risk and Diseases

Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial

Front Endocrinol (Lausanne)

Jiang W, Wang J, Li J, Li Y, Zhang Y, Xu J, Zhang J, Gao Z, Cheng J, Yang J, Chang B

doi: 10.3389/fendo.2026.1768816

Cardiovascular Risk and Diseases

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial

JAMA Cardiol

Nissen SE, Wolski K, D'Alessio D, Weerakkody G, Kiljanski J, Wiese RJ, Pavo I, Cariou B, Nicholls SJ

doi: 10.1001/jamacardio.2026.0767

Cardiovascular Risk and DiseasesFurther Publications

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: A Prespecified Secondary Analysis of the DANFLU-2 Randomized Clinical Trial

JAMA Cardiol

Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Claggett BL, Janstrup KH, Bartholdy KV, Bernholm KF, Borchsenius JIH, Davidovski FS, Davodian LW, Dons M, Duus LS, Espersen C, Fussing FH, Jensen AMR, Landler NE, Langhoff ACF, Lassen MCH, Nielsen AB, Ottosen CI, Sengeløv M, Skaarup KG, Pareek M, Solomon SD, Landray MJ, Gislason GH, Køber L, Sivapalan P, Martel CJ, Jensen JUS, Biering-Sørensen T

doi: 10.1001/jamacardio.2025.3460

COMMENTED

Cardiovascular Risk and Diseases

Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes: a longitudinal cohort study of Swedish nationwide register data

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Lancet Diabetes Endocrinol

Patsoukaki V, Lind L, Lampa E, Radhi S, Eeg-Olofsson K, Eliasson B, Eriksson JW

doi: 10.1016/S2213-8587(25)00165-2

Heart, Artery and Coronary Diseases

Preoperative Cardiovascular Risk and Postoperative Outcomes by Renin-Angiotensin System Inhibitor Use: A Secondary Analysis of a Randomized Clinical Trial

JAMA Cardiol

Tang J, Pirracchio R, Cholley B, Joosten A, Birckener J, Falcone J, Charbonneau H, Delaporte A, Chen D, Gayat E, Legrand M

doi: 10.1001/jamacardio.2025.1920

Cardiovascular Risk and Diseases

Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies

Ann Intern Med

Saeed A, Mulukutla SR, Thoma F, Lemon L, Koczo A, Reis S, Marroquin O, Kip K

doi: 10.7326/ANNALS-24-00775

Heart, Artery and Coronary Diseases

Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial

Am Heart J

Steg PG, Nicolas J, Baber U, Sartori S, Zhang Z, Feng Y, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dangas G, Dudek D, Escaned J, Gibson CM, Han YL, Huber K, Kastrati A, Kaul U, Marx SO, Kornowski R, Kunadian V, Vogel B, Oliva A, Mehta SR, Moliterno D, Sardella G, Krucoff M, Shlofmitz RA, Sharma S, Pocock S, Mehran R

doi: 10.1016/j.ahj.2025.01.016

Cardiovascular Risk and Diseases

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial

JAMA Cardiol

Nicholls SJ, Ryan DH, Deanfield J, Ferreira D, Lang CC, Lincoff AM, Lingvay I, Lübker C, Terns PP, Rasmussen S, Stensen S, Weeke PE, Kahn SE, SELECT Trial Investigators

doi: 10.1001/jamacardio.2025.4824

Related content

Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial

Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: A Prespecified Secondary Analysis of the DANFLU-2 Randomized Clinical Trial

Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes: a longitudinal cohort study of Swedish nationwide register data

Preoperative Cardiovascular Risk and Postoperative Outcomes by Renin-Angiotensin System Inhibitor Use: A Secondary Analysis of a Randomized Clinical Trial

Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies

Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial